2025 Regular Session • Connecticut Legislature
SB01473: An Act Requiring Medicaid Coverage For Fda-approved Gene Therapies To Treat Sickle Cell Disease.
Legislative Summary
To require Medicaid coverage for gene therapies approved by the federal Food and Drug Administration to treat sickle cell disease.
Demographic Impact
Overall analysis of equity impact
90% Positive
High ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
3/6/2025
Referred to Joint Committee on Human Services
Senate
3/7/2025
Public Hearing 03/11
Senate
3/14/2025
Joint Favorable
Senate
3/17/2025
Filed with Legislative Commissioners' Office
Senate
3/25/2025
Referred to Office of Legislative Research and Office of Fiscal Analysis 03/31/25 5:00 PM
Senate
4/1/2025
Reported Out of Legislative Commissioners' Office
Senate
4/1/2025
Favorable Report, Tabled for the Calendar, Senate
Senate
4/1/2025
Senate Calendar Number 235
Senate
4/1/2025
File Number 384
Senate
5/1/2025
Senate Passed
Senate
5/2/2025
Favorable Report, Tabled for the Calendar, House
House of Representatives
5/2/2025
House Calendar Number 526
House of Representatives
Roll Call Votes
Senate Roll Call Vote 105
5/1/2025
36
Yea
0
Nay
0
Not Voting
0
Absent
Result: PASSED
HS Vote Tally Sheet (Joint Favorable)
3/13/2025
17
Yea
5
Nay
0
Not Voting
1
Absent
Result: PASSED
Status Information
Current Status
Engrossed(5/1/2025)
Chamber
House of Representatives
Sponsors
Democrat: 5
Primary Sponsor
Sarah Keitt
Democrat